IdeS & EndoS: Structural Mechanism and Clinical Applications in Autoimmune Disease and Gene Therapy

IdeS, first reported in 1999, is a cysteine endopeptidase with highly specific IgG cleavage and no activity against IgM, IgA, IgD, or IgE. It is FDA-approved for preconditioning in hypersensitized kidney transplant patients. EndoS is widely used in antibody glycosylation engineering. The Nature Communications study (DOI: 10.1038/s41467-022-35340-z) established structural models for enzyme-specific IgG recognition, providing theoretical support for next-generation enzyme development.

1. Fc Engineering Overcomes Co-Crystallization Challenges

The study addressed IgG Fc self-crystallization by identifying a key E382–R255 salt bridge in the crystal lattice. Three “Fx” mutants (E382A/S/R) disrupted this contact, with E382S significantly reducing crystallization efficiency and altering the space group — clearing obstacles for enzyme–Fc complex structural analysis and providing a general strategy for studying IgG-binding proteins.

Fig. 1. Crystal packing in wild-type and “less crystallizable” IgG1 Fc fragments. Adapted from Sudol et al., Nat Commun 2022.

2. Complex Crystallization and Structural Analysis

Catalytically inactive mutants (IdeS^C94A, EndoS^D233A/E235L) were mixed with Fx variants at 1:1 molar ratio, purified by SEC, and crystallized. X-ray crystallography resolved the 3D structures of both IdeS–IgG1 Fc^E382A and EndoS–IgG1 Fc^E382R complexes, clarifying interaction interfaces and key catalytic residues.

Fig. 2. Crystal structure of IgG1 Fc^E382A–IdeS^C94A complex. Adapted from Sudol et al., Nat Commun 2022.

3. Molecular Mechanism of IdeS Recognition

IdeS binds asymmetrically to the Cγ2 domain and lower hinge of IgG1 Fc in a 1:1 monomeric stoichiometry, “clamping” the hinge to form the active site chamber. The β7–β8 loop curls upward to mediate substrate entry. Dual interfaces with Fc (A-chain 1,392 Ų; B-chain 804.7 Ų) achieve recognition via hydrogen bonds and hydrophobic interactions. The binding site overlaps with Fcγ receptors, inhibiting Fc-mediated effector functions.

4. Molecular Mechanism of EndoS Recognition

EndoS binds IgG1 Fc via a “V”-shaped structure, causing the N-glycan to “flip” from between Cγ2 domains to the exterior and embed into the glycosidase domain. The carbohydrate-binding module (CBM) binds the Cγ2–Cγ3 interface via hydrophobic interactions of W803. This forms a 2:2 complex (two EndoS molecules binding the two Fc chains separately), supporting efficient glycan hydrolysis.

Key Clinical Applications of IdeS

Guillain-Barré Syndrome (GBS)

IdeS significantly reduced nerve fiber damage in rabbit GBS models, lowered mortality, and blocked nerve injury progression by degrading pathogenic antibodies (Experimental Neurology, 2017). A 2024 multicenter clinical trial of 30 adult GBS patients receiving single-dose IdeS + IVIg showed 37% recovering independent walking within one week, with recovery 6 weeks earlier than conventional treatment and a 6.4-fold higher likelihood of independent walking at week 1.

Fig. 3. IdeS significantly improves clinical symptoms in a rabbit AMAN model. Adapted from Wang et al., Exp Neurol 2017.

AAV Gene Therapy: Overcoming Neutralizing Antibodies

Pre-existing anti-AAV neutralizing antibodies block liver transduction and prevent vector readministration. A Nature Medicine study (2020) showed IdeS efficiently cleaves anti-AAV IgG in vitro and in vivo, enabling effective liver gene transfer in passively immunized mice and non-human primates. IdeS acts as an “antibody clearance tool” that directly degrades existing antibodies without broad immunosuppression.

Fig. 4. IdeS degrades anti-AAV antibodies and enables liver transduction in IVIg-immunized mice. Adapted from Leborgne et al., Nat Med 2020.

Anti-GBM Disease: Renal Function Rescue

The GOOD-IDES Phase II study (JASN) enrolled 15 severe anti-GBM patients (eGFR ≤15 mL/min/1.73 m²) receiving a single 0.25 mg/kg IdeS dose alongside standard immunosuppression. At 6 months, most achieved dialysis-independent renal function with persistent anti-GBM antibodies below toxic thresholds and significant relief of hematuria and proteinuria.

Fig. 5. Temporal trends of donor-specific antibody (DSA) levels in select patients. Adapted from JASN.

Application Prospects

Related Products

References

1. Wang Y, et al. Exp Neurol. 2017;291:134–140. DOI: 10.1016/j.expneurol.2017.02.010

2. Lonze BE, et al. Ann Surg. 2018;268(3):488–496. DOI: 10.1097/SLA.0000000000002924

3. Leborgne C, et al. Nat Med. 2020;26(7):1096–1101. DOI: 10.1038/s41591-020-0911-7

4. Sudol ASL, et al. Nat Commun. 2022;13:7801. DOI: 10.1038/s41467-022-35340-z